Endoscopic Nd

YAG laser palliation of malignant duodenal tumors

Mark A. Laukka, Kenneth Ke Ning Wang

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This study assesses the outcome of 20 patients referred for neodymium: yttrium-aluminum-garnet laser therapy of malignant duodenal tumors between 1984 and 1992. Almost all (95%) of these patients required palliative therapy for gastrointestinal hemorrhage, and nearly half (45%) also had obstructive symptoms. A mean of 3 (range, 1 to 6) laser treatment sessions were required for palliation. Laser therapy eliminated the need for blood transfusions in only 38% of patients. Obstructive symptoms were improved in all patients after laser treatment. Treatment failure could not be predicted on the basis of demographic factors (other than age), tumor characteristics, or transfusion requirements. Survival after laser therapy was 30% at 6 months and 15% at 12 months. Endoscopic neodymium:yttrium-aluminum-garnet laser therapy is a reasonable approach for palliation of malignant tumor obstruction or hemorrhage in selected cases; however, hemorrhage often continues. (Gastrointest Endosc 1995;41:225-9.).

Original languageEnglish (US)
Pages (from-to)225-229
Number of pages5
JournalGastrointestinal Endoscopy
Volume41
Issue number3
DOIs
StatePublished - 1995

Fingerprint

Solid-State Lasers
Laser Therapy
Neodymium
Neoplasms
Lasers
Hemorrhage
Gastrointestinal Hemorrhage
Treatment Failure
Palliative Care
Blood Transfusion
Demography
Outcome Assessment (Health Care)
Survival
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Endoscopic Nd : YAG laser palliation of malignant duodenal tumors. / Laukka, Mark A.; Wang, Kenneth Ke Ning.

In: Gastrointestinal Endoscopy, Vol. 41, No. 3, 1995, p. 225-229.

Research output: Contribution to journalArticle

@article{d7e8a2ad9a484d71b755375ea9099870,
title = "Endoscopic Nd: YAG laser palliation of malignant duodenal tumors",
abstract = "This study assesses the outcome of 20 patients referred for neodymium: yttrium-aluminum-garnet laser therapy of malignant duodenal tumors between 1984 and 1992. Almost all (95{\%}) of these patients required palliative therapy for gastrointestinal hemorrhage, and nearly half (45{\%}) also had obstructive symptoms. A mean of 3 (range, 1 to 6) laser treatment sessions were required for palliation. Laser therapy eliminated the need for blood transfusions in only 38{\%} of patients. Obstructive symptoms were improved in all patients after laser treatment. Treatment failure could not be predicted on the basis of demographic factors (other than age), tumor characteristics, or transfusion requirements. Survival after laser therapy was 30{\%} at 6 months and 15{\%} at 12 months. Endoscopic neodymium:yttrium-aluminum-garnet laser therapy is a reasonable approach for palliation of malignant tumor obstruction or hemorrhage in selected cases; however, hemorrhage often continues. (Gastrointest Endosc 1995;41:225-9.).",
author = "Laukka, {Mark A.} and Wang, {Kenneth Ke Ning}",
year = "1995",
doi = "10.1016/S0016-5107(95)70342-X",
language = "English (US)",
volume = "41",
pages = "225--229",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Endoscopic Nd

T2 - YAG laser palliation of malignant duodenal tumors

AU - Laukka, Mark A.

AU - Wang, Kenneth Ke Ning

PY - 1995

Y1 - 1995

N2 - This study assesses the outcome of 20 patients referred for neodymium: yttrium-aluminum-garnet laser therapy of malignant duodenal tumors between 1984 and 1992. Almost all (95%) of these patients required palliative therapy for gastrointestinal hemorrhage, and nearly half (45%) also had obstructive symptoms. A mean of 3 (range, 1 to 6) laser treatment sessions were required for palliation. Laser therapy eliminated the need for blood transfusions in only 38% of patients. Obstructive symptoms were improved in all patients after laser treatment. Treatment failure could not be predicted on the basis of demographic factors (other than age), tumor characteristics, or transfusion requirements. Survival after laser therapy was 30% at 6 months and 15% at 12 months. Endoscopic neodymium:yttrium-aluminum-garnet laser therapy is a reasonable approach for palliation of malignant tumor obstruction or hemorrhage in selected cases; however, hemorrhage often continues. (Gastrointest Endosc 1995;41:225-9.).

AB - This study assesses the outcome of 20 patients referred for neodymium: yttrium-aluminum-garnet laser therapy of malignant duodenal tumors between 1984 and 1992. Almost all (95%) of these patients required palliative therapy for gastrointestinal hemorrhage, and nearly half (45%) also had obstructive symptoms. A mean of 3 (range, 1 to 6) laser treatment sessions were required for palliation. Laser therapy eliminated the need for blood transfusions in only 38% of patients. Obstructive symptoms were improved in all patients after laser treatment. Treatment failure could not be predicted on the basis of demographic factors (other than age), tumor characteristics, or transfusion requirements. Survival after laser therapy was 30% at 6 months and 15% at 12 months. Endoscopic neodymium:yttrium-aluminum-garnet laser therapy is a reasonable approach for palliation of malignant tumor obstruction or hemorrhage in selected cases; however, hemorrhage often continues. (Gastrointest Endosc 1995;41:225-9.).

UR - http://www.scopus.com/inward/record.url?scp=0028946687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028946687&partnerID=8YFLogxK

U2 - 10.1016/S0016-5107(95)70342-X

DO - 10.1016/S0016-5107(95)70342-X

M3 - Article

VL - 41

SP - 225

EP - 229

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 3

ER -